Bausch Health Companies Inc.(BHC)Earnings, Financials & Key RatiosBausch Health Companies Inc. (BHC) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's extreme leverage, indicated by a 25.84 debt-to-EBITDA ratio, creates an unsustainable risk profile that outweighs the potential for top-line growth.
Bausch Health Companies Inc. (BHC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Bausch Health Companies Inc. (BHC) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.78vs $0.81-3.7% | $2.5Bvs $2.4B+4.3% |
| Q1 2026 | Feb 18, 2026 | $1.08vs $1.21-10.7% | $2.8Bvs $2.7B+2.1% |
| Q4 2025 | Oct 29, 2025 | $1.16vs $1.07+8.4% | $2.7Bvs $2.7B-1.0% |
| Q3 2025 | Jul 30, 2025 | $0.90vs $0.97-7.2% | $2.5Bvs $2.6B-2.1% |
Recent stock market news and headlines for Bausch Health Companies Inc. (BHC)
LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m.
LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC. "We thank Michael for his valued service and wish him the best in his new role," said John A.
Key metrics vs top competitors for Bausch Health Companies Inc. (BHC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.91 | $1.83B | 11.42 | 8.53% | 1.53% | 588.24% | — | |
| $50.42 | $2.39B | 12.90 | -4.31% | 17.48% | 10.29% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $17.10 | $6.1B | -16.76 | 6.47% | -4.21% | -3.37% | — | |
| $71.89 | $14.02B | 38.44 | 5.06% | 5.57% | 2.84% | — | |
| $95.84 | $166.94B | 25.76 | 5.67% | 13.91% | 12.09% | — |
Bausch Health Companies Inc. (BHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Bausch Health Companies Inc. (BHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 29, 2026·SEC
Mar 2, 2026·SEC
Feb 18, 2026·SEC
Get notified when BHC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bausch Health Companies Inc. (BHC) stock FAQ — growth, dividends, profitability & financials explained
Bausch Health Companies Inc. (BHC) reported $10.55B in revenue for fiscal year 2025. This represents a 15792% increase from $66.4M in 1996.
Bausch Health Companies Inc. (BHC) grew revenue by 8.5% over the past year. This is steady growth.
Bausch Health Companies Inc. (BHC) reported a net loss of $1.19B for fiscal year 2025.
Bausch Health Companies Inc. (BHC) has a return on equity (ROE) of 588.2%. This is excellent, indicating efficient use of shareholder capital.
Bausch Health Companies Inc. (BHC) generated $989.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
